S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 51
- Registration Number
- NCT05162755
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 75
- Registration Number
- NCT04956666
- Locations
- 🇷🇺
Regional Children Clinical Hospital, Ekaterinburg, Russian Federation
🇷🇺Children Regional Clinical Hospital, Krasnodar, Russian Federation
🇷🇺Regional Children Hospital, Nizhny Novgorod, Russian Federation
A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 89
- Registration Number
- NCT04954326
- Locations
- 🇷🇺
Children Regional Clinical Hospital, Krasnodar, Russian Federation
🇷🇺Regional Children Clinical Hospital, Ekaterinburg, Russian Federation
🇷🇺Russian Children Clinical Hospital, Moscow, Russian Federation
SPARK-ALL: Calaspargase Pegol in Adults With ALL
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 122
- Registration Number
- NCT04817761
- Locations
- 🇺🇸
West Virginia University Cancer Institute, Morgantown, West Virginia, United States
🇺🇸HonorHealth Cancer Transplant Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 100
- Registration Number
- NCT04744636
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 57
- Registration Number
- NCT04742101
- Locations
- 🇰🇷
Seoul National University Hospital - Department of Hematology-Oncology, Seoul, Korea, Republic of
🇵🇱Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie Klinika Transplantacji Szpiku i Onkohematologii pokoj 4.041 ul. Wybrzeze Armii Krajowej 15, Gliwice, Poland
🇪🇸C. Universidad de Navarra Servicio de Hematologia, Pamplona, Spain
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 17
- Registration Number
- NCT04629443
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center Department of Leukemia, Division of Cancer Medicine, Houston, Texas, United States
🇦🇺Victorian Comprehensive Cancer Centre, Melbourne, Australia
🇫🇷Hôpital Saint Antoine, Paris, France
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 48
- Registration Number
- NCT04605978
- Locations
- 🇫🇷
Hôpital Laribiosière, Paris, France
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇬🇧Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 146
- Registration Number
- NCT04591808
- Locations
- 🇺🇦
Medical center ''CONSILIUM MEDICAL'', Kyiv, Ukraine
🇺🇦Private Small-Scale Enterprise Medical Center "Pulse", Vinnytsya, Ukraine
🇷🇺Saint Petersburg state budgetary institution of healthcare "City policlinic #109", Saint Petersburg, Russian Federation
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 331
- Registration Number
- NCT04164901
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada